Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in type 2 diabetes

被引：131

作者：

Horowitz, Michael ^{[1
]}

Flint, Anne ^{[2
]}

Jones, Karen L. ^{[1
]}

Hindsberger, Charlotte ^{[2
]}

Rasmussen, Mads F. ^{[2
]}

Kapitza, Christoph ^{[3
]}

Doran, Selena ^{[1
]}

Jax, Thomas ^{[3
]}

Zdravkovic, Milan ^{[2
]}

Chapman, Ian M. ^{[1
]}

机构：

[1] Univ Adelaide, Discipline Med, Royal Adelaide Hosp, Adelaide, SA 5000, Australia

[2] Novo Nordisk AS, Bagsvaerd, Denmark

[3] Profil Inst Stoffwechselforsch GmbH, Neuss, Germany

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2012年 / 97卷 / 02期

关键词：

Liraglutide; Glucagon-like peptide-1; Appetite; Energy intake; Gastric emptying; GLUCAGON-LIKE PEPTIDE-1; BETA-CELL FUNCTION; FOOD-INTAKE; ANTRAL AREA; POSTPRANDIAL GLUCOSE; PROMOTES SATIETY; BODY-WEIGHT; 7-36; AMIDE; METABOLISM; EXENATIDE;

D O I：

10.1016/j.diabres.2012.02.016

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aims: Liraglutide reduces bodyweight in patients with type 2 diabetes mellitus (T2DM). This study aimed to investigate the mechanisms underlying this effect. Methods: The comparative effects of liraglutide, glimepiride and placebo on energy intake, appetite, nausea, gastric emptying, antral distension, bodyweight, gastrointestinal hormones, fasting plasma glucose and resting energy expenditure (REE), were assessed in subjects with T2DM randomised to treatment A (liraglutide-placebo), B (placebo-glimepiride) or C (glimepiride-liraglutide). Assessments were performed at the end of each 4-week treatment period. Results: Energy intake was less (NS) with liraglutide vs placebo and glimepiride, and 24-h REE was higher (NS) with liraglutide vs placebo and glimepiride. Fasting hunger was less (p = 0.01) with liraglutide vs placebo and glimepiride, and meal duration was shorter with liraglutide (p = 0.002) vs placebo. Paracetamol AUC(0-60min) and C-max were less (p < 0.01) and fasting peptide YY was lower (p <= 0.001) after liraglutide vs placebo and glimepiride. Bodyweight reductions of 1.3 and 2.0 kg were observed with liraglutide vs placebo and glimepiride (p < 0.001). There were no differences on antral distension, nausea, or other gastro-intestinal hormones. Conclusion: Liraglutide caused decreased gastric emptying and increased reduction in bodyweight. The mechanisms of the liraglutide-induced weight-loss may involve a combined effect on energy intake and energy expenditure. (C) 2012 Elsevier Ireland Ltd. All rights reserved.

引用

页码：258 / 266

页数：9

共 47 条

[1] The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway [J].

Abbott, CR ;

Monteiro, M ;

Small, CJ ;

Sajedi, A ;

Smith, KL ;

Parkinson, JRC ;

Ghatei, MA ;

Bloom, SR .

BRAIN RESEARCH, 2005, 1044 (01) :127-131

[2]

[Anonymous], ICH HARM TRIP GUID G

[3] Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].

Astrup, Arne ;

Rossner, Stephan ;

Van Gaal, Luc ;

Rissanen, Aila ;

Niskanen, Leo ;

Al Hakim, Mazin ;

Madsen, Jesper ;

Rasmussen, Mads F. ;

Lean, Michael E. J. .

LANCET, 2009, 374 (9701) :1606-1616

[4] Gut hormone PYY3-36 physiologically inhibits food intake [J].

Batterham, RL ;

Cowley, MA ;

Small, CJ ;

Herzog, H ;

Cohen, MA ;

Dakin, CL ;

Wren, AM ;

Brynes, AE ;

Low, MJ ;

Ghatei, MA ;

Cone, RD ;

Bloom, SR .

NATURE, 2002, 418 (6898) :650-654

[5] Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) [J].

Buse, John B. ;

Rosenstock, Julio ;

Sesti, Giorgio ;

Schmidt, Wolfgang E. ;

Montanya, Eduard ;

Brett, Jason H. ;

Zychma, Marcin ;

Blonde, Lawrence .

LANCET, 2009, 374 (9683) :39-47

[6] Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes [J].

Chapman, I ;

Parker, B ;

Doran, S ;

Feinle-Bisset, C ;

Wishart, J ;

Strobel, S ;

Wang, Y ;

Burns, C ;

Lush, C ;

Weyer, C ;

Horowitz, M .

DIABETOLOGIA, 2005, 48 (05) :838-848

[7] Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia [J].

Deane, Adam M. ;

Nguyen, Nam Q. ;

Stevens, Julie E. ;

Fraser, Robert J. L. ;

Holloway, Richard H. ;

Besanko, Laura K. ;

Burgstad, Carly ;

Jones, Karen L. ;

Chapman, Marianne J. ;

Rayner, Chris K. ;

Horowitz, Michael .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (01) :215-221

[8]

DeFronzo RA, 2008, CURR MED RES OPIN, V24, P2943, DOI [10.1185/03007990802418851, 10.1185/03007990802418851 ]

[9] One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α- and β-cell function and reduces endogenous glucose release in patients with type 2 diabetes [J].

Degn, KB ;

Juhl, CB ;

Sturis, J ;

Jakobsen, G ;

Brock, B ;

Chandramouli, V ;

Rungby, J ;

Landau, BR ;

Schmitz, O .

DIABETES, 2004, 53 (05) :1187-1194

[10] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].

Drucker, Daniel J. ;

Nauck, Michael A. .

LANCET, 2006, 368 (9548) :1696-1705

← 1 2 3 4 5 →